Sign In
Buy PALI
$1.93
+0.0700 (+3.76%)
At Close: Jun 03, 2026
Former Leading BioSciences Chairman and Retired Board-Certified Surgeon, Dr. David Berry to Serve as Chair Former Leading BioSciences Chairman and Retired Board-Certified Surgeon, Dr. David Berry to S
Palisade Bio Stock Shoots Up On FDA Fast Track Tag For LB1148 For Reduction of Post-Operative Adhesions
09:23am, Thursday, 13'th May 2021
The FDA has granted Fast Track Designation to Palisade Bio Inc's (NASDAQ: PALI) investigational drug LB1148, which has the potential to be the first oral treatment to reduce adhesions following a
Palisade Bio (PALI) Stock: Over 25% Increase Pre-Market Explanation
08:23am, Thursday, 13'th May 2021
The stock price of Palisade Bio, Inc. (Nasdaq: PALI) increased by over 25% pre-market. This is why it happened.
Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery
07:00am, Thursday, 13'th May 2021
LB1148 was previously granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of postoperative GI dysfunction associated with pediatric cardiovascular surgery
Palisade Bio and Newsoara Announce Completion of Phase 2 Study in GI Surgery Study in China
09:07am, Friday, 07'th May 2021
Topline results expected in H1-2021 Topline results expected in H1-2021
